Trials / Completed
CompletedNCT02942160
EN3835 for the Treatment of Edematous Fibrosclerotic Panniculopathy (Commonly Known as Cellulite)
A Phase 2, Open-Label Extension Study of EN3835 in the Treatment of Edematous Fibrosclerotic Panniculopathy
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 259 (actual)
- Sponsor
- Endo Pharmaceuticals · Industry
- Sex
- Female
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
A Phase 2, Open-Label Extension Study of EN3835 in the Treatment of Edematous Fibrosclerotic Panniculopathy (commonly known as Cellulite).
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| BIOLOGICAL | Collagenase Clostridium Histolyticum |
Timeline
- Start date
- 2016-10-05
- Primary completion
- 2018-06-14
- Completion
- 2018-06-14
- First posted
- 2016-10-21
- Last updated
- 2020-11-24
- Results posted
- 2020-11-24
Locations
15 sites across 1 country: United States
Source: ClinicalTrials.gov record NCT02942160. Inclusion in this directory is not an endorsement.